Vanda Pharmaceuticals (VNDA) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.27 -1.13%
EPS Growth %: -60.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
SUNB, CULP, KFY, More
EPS Growth %: -60.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $8.07 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
- Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook
- J.Jill (JILL) Tops Q2 EPS by 67c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
